Aardvark Pauses ARD-101 Phase 3 HERO Trial Enrollment

The latest announcement is out from Aardvark Therapeutics, Inc. ( (AARD) ).

On February 27, 2026, Aardvark Therapeutics said it had voluntarily paused enrollment and dosing in its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, along with the related open-label extension study. The move followed reversible cardiac findings at above-target therapeutic doses in a separate healthy volunteer study, triggering a comprehensive data review and a delay to the previously expected third-quarter 2026 topline readout.

Management emphasized that patient safety is the highest priority and that it remains committed to advancing ARD-101 while reassessing optimal dosing and working closely with regulators and clinical experts. The pause, while precautionary, introduces timing uncertainty for Aardvark’s lead program in a rare disease setting where ARD-101 holds Orphan Drug and Rare Pediatric Disease designations, potentially affecting expectations for the company’s near-term clinical and strategic milestones.

The most recent analyst rating on (AARD) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.

Spark’s Take on AARD Stock

According to Spark, TipRanks’ AI Analyst, AARD is a Neutral.

The score is held back primarily by weak financial performance (pre-revenue, widening losses, and substantial cash burn implying funding risk). Offsetting factors include favorable technical momentum (price above major moving averages with positive MACD) and positive corporate pipeline milestones (Phase 3 HERO trial progress and updated program communications), while valuation remains constrained by ongoing losses and a negative P/E.

To see Spark’s full report on AARD stock, click here.

More about Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule drugs to suppress hunger for Prader-Willi Syndrome and broader metabolic diseases. Its lead oral candidate, ARD-101, is in late-stage development for hyperphagia in PWS, while ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, is being advanced through Phase 2 trials targeting limitations of existing GLP-1-based obesity treatments.

The company’s approach focuses on hunger-specific neural pathways, distinct from appetite-driven reward mechanisms, and explores complementary use with anti-appetite therapies. ARD-101, a gut-restricted bitter taste receptor agonist that stimulates gut hormones such as GLP-1 and CCK, has received Orphan Drug and Rare Pediatric Disease designations from the FDA for PWS, underscoring its focus on rare metabolic indications and potential regulatory advantages.

Average Trading Volume: 188,388

Technical Sentiment Signal: Strong Buy

Current Market Cap: $276.1M

See more data about AARD stock on TipRanks’ Stock Analysis page.